JMP Securities Reiterates Market Outperform on Werewolf Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $12 price target.
June 26, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Werewolf Therapeutics and maintained a $12 price target, indicating confidence in the company's future performance.
The reiteration of a Market Outperform rating and the maintenance of a $12 price target by JMP Securities suggests strong confidence in Werewolf Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100